EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure

Sachindra R Joshi, Elif Karaca Atabay, Jun Liu, Yan Ding, Steven D Briscoe, Mark J Alexander, Patrick Andre, Ravindra Kumar, Gang Li

Frontiers in Cardiovascular Medicine · 23.02.2023 · 10

DOI: 10.3389/fcvm.2023.1064290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 23.02.2023. Verfasst von Sachindra R Joshi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent manifestation of PH but lacks any approved treatment. Activin receptor type IIA-Fc fusion protein (ActRIIA-Fc) was found previously to be efficacious in experimental and human pulmonary arterial hypertension (PAH). Here we tested the hypothesis that ActRIIA-Fc improves pulmonary vascular remodeling and alleviates PH in models of PH-LHD, specifically in subtypes of heart failure with reduced ejection fraction (PH-HFrEF) and preserved ejection fraction (PH-HFpEF). Treatment with murine ActRIIA-Fc reduced cardiac remodeling and improved cardiac function in two mouse models of left heart disease without PH, confirming that this inhibitor of activin-class ligand signaling can exert cardioprotective effects in heart failure. In a mouse model of PH-HFrEF with prolonged pressure overload caused by transverse aortic constriction, ActRIIA-Fc treatment significantly reduced pulmonary vascular remodeling, pulmonary fibrosis, and pulmonary hypertension while exerting beneficial structural, functional, and histological effects on both the left and right heart. Additionally, in an obese ZSF1-SU5416 rat model of PH-HFpEF with metabolic dysregulation, therapeutic treatment with ActRIIA-Fc normalized SMAD3 overactivation in pulmonary vascular and perivascular cells, reversed pathologic pulmonary vascular and cardiac remodeling, improved pulmonary and cardiac fibrosis, alleviated PH, and produced marked functional improvements in both cardiac ventricles. Studies in vitro revealed that treatment with ActRIIA-Fc prevents an abnormal, glucose-induced, activin-mediated, migratory phenotype in human pulmonary artery smooth muscle cells, providing a mechanism by which ActRIIA-Fc could exert therapeutic effects in experimental PH-HFpEF with metabolic dysregulation. Our results demonstrate that ActRIIA-Fc broadly corrects cardiopulmonary structure and function in experimental PH-LHD, including models of PH-HFrEF and PH-HFpEF, leading to alleviation of PH under diverse pathophysiological conditions. These findings highlight the important pathogenic contributions of activin-class ligands in multiple forms of experimental PH and support ongoing clinical evaluation of human ActRIIA-Fc (sotatercept) in patients with PH-HFpEF.

Schlagwörter

Stichwörter der Autor:innen

ActRIIA-FcGroup 2 pulmonary hypertension (PH)activinheart failure with preserved ejection fractionheart failure with reduced ejection fractionpulmonary arterial hypertensionsmooth muscle cellvascular remodeling

Autor:innen und Institutionen

  • Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.

Zitieren

APA

Joshi, S. R., Atabay, E. K., Liu, J., Ding, Y., Briscoe, S. D., Alexander, M. J., Andre, P., Kumar, R., & Li, G. (2023). Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1064290

Vancouver

Joshi SR, Atabay EK, Liu J, Ding Y, Briscoe SD, Alexander MJ, et al. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1064290

BibTeX
@article{Joshi2023,
  author = {Joshi, Sachindra R and Atabay, Elif Karaca and Liu, Jun and Ding, Yan and Briscoe, Steven D and Alexander, Mark J and Andre, Patrick and Kumar, Ravindra and Li, Gang},
  title = {Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  volume = {10},
  doi = {10.3389/fcvm.2023.1064290}
}
Kostenlos starten →